Table 3.
Sensitivity Analysis Comparing IORT versus Non-IORT
| Stratified analysis | No. Studies | No. Patients | Pooled MSR/RR (95% CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (%) | P value | |||||
| (1) Analysis for MST | ||||||
| By publication year: | ||||||
| After 2000y | 5 | 467 | 1.22 (1.07 to 1.40) | 0.004 | 46.2 | 0.098 |
| Before 2000y | 8 | 296 | 1.18 (0.94 to 1,49) | 0.144 | 73.4 | 0.000 |
| By sample size: | ||||||
| > 30 | 9 | 617 | 1.17 (1.06 to 1.29) | 0.002 | 29.0 | 0.187 |
| ≤ 30 | 6 | 146 | 1.28 (0.88 to 1.85) | 0.195 | 80.6 | 0.000 |
| By NOS score: | ||||||
| > 6 | 10 | 594 | 1.27 (1.09 to 1.47) | 0.002 | 64.1 | 0.001 |
| ≤ 6 | 3 | 169 | 1.00 (0.83 to 1.20) | 0.970 | 27.9 | 0.250 |
| By study location: | ||||||
| America | 3 | 168 | 1.18 (0.92 to 1.51) | 0.189 | 56.7 | 0.074 |
| Europe | 3 | 279 | 1.17 (0.99 to 1.39) | 0.072 | 34.1 | 0.219 |
| Asian | 7 | 316 | 1.24 (0.98 to 1.56) | 0.068 | 75.1 | 0.000 |
| (2) Analysis for LR | ||||||
| By publication year: | ||||||
| After 2000y | 5 | 389 | 0.63 (0.41 to 0.96) | 0.033 | 33.4 | 0.199 |
| Before 2000y | 3 | 66 | 0.77 (0.39 to 1.50) | 0.439 | 37.9 | 0.200 |
| By sample size: | ||||||
| > 30 | 6 | 437 | 0.72 (0.52 to 1.02) | 0.061 | 43.3 | 0.117 |
| ≤ 30 | 2 | 18 | 0.43 (0.08 to 2.26) | 0.316 | 43.2 | 0.185 |
| By NOS score: | ||||||
| > 6 | 6 | 312 | 0.69 (0.45 to 1.05) | 0.082 | 52.4 | 0.062 |
| ≤ 6 | 2 | 77 | 0.62 (0.34 to 1.14) | 0.127 | 0.0 | 0.862 |
| By study location: | ||||||
| America | 3 | 118 | 0.69 (0.41 to 1.14) | 0.147 | 0.0 | 0.841 |
| Europe | 3 | 282 | 0.45 (0.17 to 1.18) | 0.106 | 65.5 | 0.055 |
| Asian | 2 | 55 | 0.51 (0.06 to 4.08) | 0.524 | 64.8 | 0.092 |
| (3) Analysis for complications | ||||||
| By publication year: | ||||||
| After 2000y | 5 | 432 | 1.33 (0.32 to 5.46) | 0.697 | 14.5 | 0.311 |
| Before 2000y | 3 | 77 | 0.94 (0.71 to 1.25) | 0.684 | 27.4 | 0.239 |
| By sample size: | ||||||
| > 30 | 6 | 466 | 0.92 (0.72 to 1.19) | 0.543 | 16.2 | 0.309 |
| ≤ 30 | 2 | 43 | 2.57 (0.50 to 13.3) | 0.259 | 0.0 | 0.425 |
| By NOS score: | ||||||
| > 6 | 6 | 396 | 0.87 (0.69 to 1.10) | 0.240 | 2.7 | 0.399 |
| ≤ 6 | 2 | 113 | 1.51 (0.48 to 4.82) | 0.482 | 38 | 0.204 |
| By study location: | ||||||
| America | 2 | 124 | 0.77 (0.31 to 1.93) | 0.582 | 62.9 | 0.101 |
| Europe | 4 | 338 | 1.08 (0.70 to 1.67) | 0.728 | 42.8 | 0.155 |
| Asian | 2 | 47 | 0.65 (0.12 to 3.35) | 0.603 | 0.0 | 0.549 |
| (4) Analysis for Mortality | ||||||
| By publication year: | ||||||
| After 2000y | 4 | 392 | 1.20 (0.43 to 3.31) | 0.726 | 0.0 | 0.503 |
| Before 2000y | 3 | 87 | 0.71 (0.10 to 4.93) | 0.727 | 0.0 | 0.417 |
| By sample size: | ||||||
| > 30 | 4 | 392 | 1.20 (0.43 to 3.31) | 0.503 | 0.0 | 0.503 |
| ≤ 30 | 3 | 86 | 0.71 (0.10 to 4.93) | 0.417 | 0.0 | 0.417 |
| By NOS score: | ||||||
| > 6 | 5 | 366 | 0.84 (0.31 to 2.30) | 0.731 | 0.0 | 0.671 |
| ≤ 6 | 2 | 113 | 2.80 (0.38 to 20.7) | 0.312 | 0.0 | 0.483 |
| By study location: | ||||||
| America | 2 | 127 | 1.31 (0.07 to 25.0) | 0.856 | 51 | 0.153 |
| Europe | 4 | 339 | 1.03 (0.38 to 2.81) | 0.951 | 0.0 | 0.780 |
| Asian | 1 | 13 | Not estimable | Not estimable | Not estimable | Not estimable |
MST indicates median survival time, LR local recurrence, NOS Newcastle-Ottawa Scale